2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-
2021
Systematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients
Charalel RA, Sung J, Askin G, Jo J, Mitry M, Chung C, Tmanova L, Madoff DC. Systematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients. Current Oncology Reports 2021, 23: 135. PMID: 34716800, DOI: 10.1007/s11912-021-01075-1.Peer-Reviewed Original ResearchConceptsPortal vein embolizationAssociated liver partitionPortal vein ligationHepatocellular carcinoma patientsSystematic reviewVein embolizationCarcinoma patientsMajor complicationsPooled proportionVein ligationLiver partitionLow major complication rateMajor complication ratePurpose of ReviewToRandom-effects modelWeb of ScienceEffective hypertrophyFLR hypertrophyComplication rateOvid EmbaseCochrane LibraryHCC patientsLiver hypertrophyOvid MEDLINEInclusion criteria